Actualités

(Bloomberg) -- Nscale is telling prospective investors it has about $51 billion of total contracted revenue ahead of a US initial public offering that could take place as soon as in September, according to people familiar with the matter.Most Read from BloombergIran Says Agreement on Hormuz Shipping Reached With OmanGoogle AI Veterans Depart During Seismic Leadership ShiftWhy Do Data Centers Use So Much Fresh Water?Microsoft’s AI Sales Mostly Come From OpenAI, Disclosures ShowOpenAI Models Joine

As SpaceX stock has tumbled since its record-setting IPO, shares of newly public smaller companies have soared.

Anthropic's IPO could generate strong tailwinds for Amazon's business.

Anna Cooban reports on the British government’s decision to clear Paramount Skydance’s $110 billion takeover of Warner Bros. Discovery due to assurances on media diversity from the company.

SpaceX shares seesawed on Thursday as investors weighed the impact of insider selling on the stock, which has had a ‌turbulent run since its market debut. When a company goes public, its executives, employees and early investors are ​typically barred from selling their shares for up to 180 days under lock-up agreements designed to curb volatility and support the stock. SpaceX, however, had an unusual arrangement under which up to 20% of the restricted shares could be sold starting Thursday, the second trading day after its second-quarter earnings release.

The 216-unit Village on the Green property in Atlanta was the first deal the company analyzed, the firm’s founder tells Multifamily Dive.

Nearly 912 Million SpaceX Shares Unlocked as Lockup Begins to Expire

The British government has cleared Paramount Skydance’s $110 billion takeover of Warner Bros. Discovery, saying it had received assurances from the company over media diversity.

(Update with Paramount's statement in the penultimate paragraph.) The UK's Competition and Market

Thousands of retail investors bought what they were told was pre-IPO SpaceX exposure, only to discover the shares beneath them had already been sold, stacked, or may never have existed at all. The lockup clock just started, and the reckoning is arriving in a falling market.

Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.

Thursday’s lockup expiration could more than double SpaceX’s public float, with up to 912 million shares becoming eligible for sale.

Vast, a Chinese artificial-intelligence unicorn backed by technology titans Alibaba and Baidu, is in talks with investors to get fresh capital, people familiar with the matter say.

Polymarket traders give just 18% odds to a Tesla-SpaceX merger in 2026. Here is why skepticism runs so deep.

The online marketplace reported higher revenue of $3.13 billion, and now expects gross merchandise volume to grow between 11.5% and 12.5% in 2026.

Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.

Chinese memory maker CXMT went public and gained nearly 500% on its opening day.

Chipotle Mexican Grill removed jalapeño peppers from Minnesota locations after a Salmonella outbreak linked to its restaurants. The company is working with health authorities and has shifted to an alternative supplier for jalapeños. The incident raises fresh questions around food safety practices and potential operational disruption for NYSE:CMG. Chipotle Mexican Grill, trading on the NYSE as NYSE:CMG, is again in the spotlight after the Salmonella outbreak tied to jalapeño peppers in...

AGX's $8.3 million ValCor acquisition gives Teledata a New England foothold, skilled workers and access to defense, aerospace and tech customers.

Chipotle Mexican Grill stock is valued above the market on earnings while running a thinner margin, and the growth paying for that gap now comes mostly from opening restaurants.

According to a Reuters report, a senior source denied merger discussions between AstraZeneca and Bristol Myers Squibb.

Chipotle's share price has swung wildly for two years, and now management is buying back stock aggressively near current levels while Wall Street eyes a 27% upside. The real question is whether the operational recovery has enough traction to survive margin pressure, a fragile consumer, and fresh food safety concerns.

The March start date means Paramount will owe more than $1 billion in daily penalties before a judge ever rules on the deal

CRH expands its Utah footprint with Pisgah Stone Products, adding long-life limestone reserves to support aggregates growth in a high-demand market.

Chipotle Mexican Grill (NYSE:CMG) rose around 3. 5% in pre-market trading on Wednesday after Minnesota health officials said they have no ongoing concerns about the company following a recent salmonella outbreak investigation.

AstraZeneca (NASDAQ:AZN) shares climbed around 6% on Wednesday after Reuters reported that there are “no discussions” between the company and Bristol Myers Squibb (NYSE:BMY) regarding a potential merger, contradicting recent speculation that had unsettled investors. The report eased concerns surrounding a deal that, if completed, would have created a pharmaceutical group valued at close to $400 billion.

Investing.com -- Chipotle Mexican Grill (NYSE: CMG) is signaling a 3.5% pre-market rebound ahead of Wednesday’s open after Minnesota health officials confirmed they have no ongoing concerns with the chain. The official clearance offers the clearest exoneration yet following Tuesday’s 9.72% plunge — the stock’s steepest single-day drop in nine months. The recovery stems from an August 5 SEC filing in which Chipotle revealed that the Minnesota Department of Health (MDH) had completely cleared it o

A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers

Chief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.

AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff on Monday when the merger speculation first emerged, while BMY shareholders were widely viewed as the primary beneficiaries of any combination.